203 related articles for article (PubMed ID: 16182380)
21. The influence of HIV infection on the correlation between plasma concentrations of monocyte chemoattractant protein-1 and carotid atherosclerosis.
Joven J; Coll B; Tous M; Ferré N; Alonso-Villaverde C; Parra S; Camps J
Clin Chim Acta; 2006 Jun; 368(1-2):114-9. PubMed ID: 16445900
[TBL] [Abstract][Full Text] [Related]
22. Cerebrospinal fluid viral loads reach less than 2 copies/ml in HIV-1-infected patients with effective antiretroviral therapy.
Yilmaz A; Svennerholm B; Hagberg L; Gisslén M
Antivir Ther; 2006; 11(7):833-7. PubMed ID: 17302245
[TBL] [Abstract][Full Text] [Related]
23. Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment.
Mellgren A; Antinori A; Cinque P; Price RW; Eggers C; Hagberg L; Gisslén M
Antivir Ther; 2005; 10(6):701-7. PubMed ID: 16218168
[TBL] [Abstract][Full Text] [Related]
24. Antiretroviral treatment reduces increased CSF neurofilament protein (NFL) in HIV-1 infection.
Mellgren A; Price RW; Hagberg L; Rosengren L; Brew BJ; Gisslén M
Neurology; 2007 Oct; 69(15):1536-41. PubMed ID: 17923616
[TBL] [Abstract][Full Text] [Related]
25. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders.
Letendre SL; McCutchan JA; Childers ME; Woods SP; Lazzaretto D; Heaton RK; Grant I; Ellis RJ;
Ann Neurol; 2004 Sep; 56(3):416-23. PubMed ID: 15349869
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of nelfinavir-based treatment in the central nervous system of HIV-1 infected patients.
Karlström O; Ståhle L; Perrin L; Tegude H; Sönnerborg A
Scand J Infect Dis; 2006; 38(5):371-4. PubMed ID: 16709540
[TBL] [Abstract][Full Text] [Related]
27. Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma.
Marcelin AG; Tubiana R; Lambert-Niclot S; Lefebvre G; Dominguez S; Bonmarchand M; Vauthier-Brouzes D; Marguet F; Mousset-Simeon N; Peytavin G; Poirot C
AIDS; 2008 Aug; 22(13):1677-9. PubMed ID: 18670231
[TBL] [Abstract][Full Text] [Related]
28. Quantification of infectious HIV-1 plasma viral load using a boosted in vitro infection protocol.
Rusert P; Fischer M; Joos B; Leemann C; Kuster H; Flepp M; Bonhoeffer S; Günthard HF; Trkola A
Virology; 2004 Aug; 326(1):113-29. PubMed ID: 15262500
[TBL] [Abstract][Full Text] [Related]
29. Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy.
Gisolf EH; van Praag RM; Jurriaans S; Portegies P; Goudsmit J; Danner SA; Lange JM; Prins JM
J Acquir Immune Defic Syndr; 2000 Dec; 25(5):426-33. PubMed ID: 11141242
[TBL] [Abstract][Full Text] [Related]
30. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
[TBL] [Abstract][Full Text] [Related]
31. Clinical comparison of branched DNA and reverse transcriptase-PCR and nucleic acid sequence-based amplification assay for the quantitation of circulating recombinant form_BC HIV-1 RNA in plasma.
Pan P; Tao X; Zhang Q; Xing W; Sun X; Pei L; Jiang Y
AIDS; 2007 Dec; 21 Suppl 8():S27-32. PubMed ID: 18172387
[TBL] [Abstract][Full Text] [Related]
32. HIV-1 RNA levels in the cerebrospinal fluid may increase owing to damage to the blood-brain barrier.
Burger DM; Boucher CA; Meenhorst PL; Kraayeveld CL; Portegies P; Mulder JW; Hoetelmans RM; Beijnen JH
Antivir Ther; 1997 Apr; 2(2):113-7. PubMed ID: 11322275
[TBL] [Abstract][Full Text] [Related]
33. HIV genetic diversity between plasma and cerebrospinal fluid in patients with HIV encephalitis.
Soulié C; Fourati S; Lambert-Niclot S; Tubiana R; Canestri A; Girard PM; Katlama C; Morand-Joubert L; Calvez V; Marcelin AG
AIDS; 2010 Sep; 24(15):2412-4. PubMed ID: 21217205
[TBL] [Abstract][Full Text] [Related]
34. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection.
Deeks SG; Hoh R; Neilands TB; Liegler T; Aweeka F; Petropoulos CJ; Grant RM; Martin JN
J Infect Dis; 2005 Nov; 192(9):1537-44. PubMed ID: 16206068
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma.
Antinori A; Perno CF; Giancola ML; Forbici F; Ippolito G; Hoetelmans RM; Piscitelli SC
Clin Infect Dis; 2005 Dec; 41(12):1787-93. PubMed ID: 16288405
[TBL] [Abstract][Full Text] [Related]
36. The relationship between plasma viral load and neuropsychological functioning in HIV-1 infection.
Reger MA; Martin DJ; Cole SL; Strauss G
Arch Clin Neuropsychol; 2005 Mar; 20(2):137-43. PubMed ID: 15708723
[TBL] [Abstract][Full Text] [Related]
37. MCP-1 in the cerebrospinal fluid of children with acute lymphoblastic leukemia.
Eisenkraft A; Keidan I; Bielorai B; Keller N; Toren A; Paret G
Leuk Res; 2006 Oct; 30(10):1259-61. PubMed ID: 16516290
[TBL] [Abstract][Full Text] [Related]
38. Antiretroviral treatment alters relationship between MCP-1 and neurometabolites in HIV patients.
Chang L; Ernst T; St Hillaire C; Conant K
Antivir Ther; 2004 Jun; 9(3):431-40. PubMed ID: 15259906
[TBL] [Abstract][Full Text] [Related]
39. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
[TBL] [Abstract][Full Text] [Related]
40. Viral load determines the B-cell response in the cerebrospinal fluid during human immunodeficiency virus infection.
Cepok S; von Geldern G; Nolting T; Grummel V; Srivastava R; Zhou D; Hartung HP; Adams O; Arendt G; Hemmer B
Ann Neurol; 2007 Nov; 62(5):458-67. PubMed ID: 17703460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
